Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Schizophr Bull. 2010 Mar;36(2):246-70. doi: 10.1093/schbul/sbp132. Epub 2009 Nov 9.

Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Author information

  • Mental Health Research Institute of Victoria, Parkville, Melbourne, Victoria 3052, Australia. m.vandenbuuse@mhri.edu.au

Abstract

In recent years, there have been huge advances in the use of genetically modified mice to study pathophysiological mechanisms involved in schizophrenia. This has allowed rapid progress in our understanding of the role of several proposed gene mechanisms in schizophrenia, and yet this research has also revealed how much still remains unresolved. Behavioral studies in genetically modified mice are reviewed with special emphasis on modeling psychotic-like behavior. I will particularly focus on observations on locomotor hyperactivity and disruptions of prepulse inhibition (PPI). Recommendations are included to address pharmacological and methodological aspects in future studies. Mouse models of dopaminergic and glutamatergic dysfunction are then discussed, reflecting the most important and widely studied neurotransmitter systems in schizophrenia. Subsequently, psychosis-like behavior in mice with modifications in the most widely studied schizophrenia susceptibility genes is reviewed. Taken together, the available studies reveal a wealth of available data which have already provided crucial new insight and mechanistic clues which could lead to new treatments or even prevention strategies for schizophrenia.

PMID:
19900963
[PubMed - indexed for MEDLINE]
PMCID:
PMC2833124
Free PMC Article

Images from this publication.See all images (2)Free text

Fig. 1.
Fig. 2.
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk